ライフサイエンスコーパス: liver function

1 gulators that play a key role in maintaining liver function.

2 e (ALT), a primary biomarker associated with liver function.

3 ncers in highly expressed genes critical for liver function.

4 ival +/- liver transplant and/or recovery of liver function.

5 formation without effects on body weight or liver function.

6 h NAFLD or steatohepatitis (NASH) may impair liver function.

7 d positive effects on biochemical markers of liver function.

8 lating metabolic gene expression for optimal liver function.

9 parameters indicative for the improvement of liver function.

10 eosin, Sudan III) were determined to monitor liver function.

11 nduced steatosis in mouse liver and improves liver function.

12 ythrocyte protoporphyrin levels and improved liver function.

13 ped and partially restored mitochondrial and liver function.

14 ding to liver fibrosis, and deterioration of liver function.

15 ulation of hepatic genes with importance for liver function.

16 trastructure of liver and providing enhanced liver function.

17 cells and hepatocytes is a prerequisite for liver function.

18 betaine, and folate) is important for normal liver function.

19 emoembolization if they still have preserved liver function.

20 c medaka may be mediated through compromised liver function.

21 and low-protein ascites with associated poor liver function.

22 mmatory biomarkers of CVD, but not kidney or liver function.

23 apid lethality despite maintenance of normal liver function.

24 roribose ([(18)F]-2-DFR), for use in imaging liver function.

25 within the Milan criteria and with adequate liver function.

26 tant and conserved regulators in maintaining liver function.

27 t alter levels of markers of liver injury or liver function.

28 use of a lack of specific imaging agents for liver function.

29 ons were observed between B cell subsets and liver function.

30 r disease, but without detrimental impact on liver function.

31 ucted to evaluate tissue damage, stress, and liver function.

32 se medicines require consistent screening of liver function.

33 tension, 69% dyslipidaemia, and 25% abnormal liver function.

34 evidence of liver cirrhosis, and compensated liver function.

35 ths, and adequate haematological, renal, and liver function.

36 he dogs showed evidence of tumors or altered liver function.

37 ther supporting a role for these proteins in liver function.

38 ionally, adiposity is associated with poorer liver function.

39 accumulation have broad effects on metabolic liver functions.

40 without damaging mitochondrial integrity and liver functions.

41 cipe processes, and yielding good phenotypic liver functions.

42 th, protect liver cells, and sustain remnant liver functions.

43 homeostasis and possibly, aggravated loss of liver functions.

44 gulate metabolic responses to maintain basic liver functions.

45 eration after surgery and for maintenance of liver functions.

46 e have many alterations in liver biology and liver functions.

47 of critical signaling pathways that control liver functions.

48 or 1alpha, which are known to be involved in liver functions.

49 ted impaired mitochondrial, peroxisomal, and liver functions.

50 All patients had normal renal and liver functions.

51 s for those with liver dysfunction vs normal liver function, 2016 vs 1510 microg/dL; P = .003).

52 also after implantation in mice with normal liver function, 60% of the time.

53 cell carcinoma (389 [12%]), rash (155 [5%]), liver function abnormalities (165 [5%]), arthralgia (106

54 l dysfunction (11.4% vs 3.3%; P = .006), and liver function abnormalities (8.1% vs 1.6%; P = .01).

55 , R3(injury) , and R4(late) correlated with liver function abnormalities.

56 er lipid accumulation and partially improved liver function after 10-week HFLMCD diet feeding.

57 All treated recipients had normal liver function after a 6-month follow-up and are well an

58 6 knockout mice (AnxA6(-/-) ), we challenged liver function after partial hepatectomy (PHx), inducing

59 Liver function after stage-1 was assessed using the crit

60 ated that isolated cells are able to restore liver function after transplantation into a cirrhotic li

61 ell as clinically measured deteriorations in liver function, all point to growing distress in this po

62 Liver function analyses revealed no indication for hepat

63 4alpha (HNF4alpha) is a master regulator of liver function and a tumor suppressor in hepatocellular

64 rnatives to liver transplantation to restore liver function and bridge patients to transplantation.

65 using NMP-L provides specific information on liver function and can permit their transplantation whil

66 ncentrated (hemoglobin 16 g/dl), with normal liver function and coagulation testing.

67 HFD induces intestinal dysbiosis and impairs liver function and coagulation, with a potential negativ

68 This review provides an overview of normal liver function and development and focuses on the eviden

69 Liver fibrosis interferes with normal liver function and facilitates hepatocellular carcinoma

70 enetic mechanisms associated with markers of liver function and hepatic steatosis, laying the groundw

71 r disease who develop rapid deterioration of liver function and high short-term mortality after an ac

72 ly decreased, lipid profiles normalized, and liver function and histology were improved.

73 ansport processes play a key role in healthy liver function and how they are affected by disease.

74 rated an effective metabolic regeneration of liver function and insulin sensitivity.

75 ng factor 3 (SRSF3) plays a critical role in liver function and its loss promotes chronic liver damag

76 as occurs in fibrosis and cirrhosis, impairs liver function and leads to disease.

77 diovascular complications can in turn affect liver function and liver disease progression.

78 t effect of these changes was improvement in liver function and markers of liver injury and the posit

79 ls of blood analytes associate with impaired liver function and muscle damage.

80 ts with multiple intrahepatic tumors or poor liver function and no major comorbidities were listed fo

81 nd late after transplantation in relation to liver function and operational tolerance.

82 In addition to tumor burden, liver function and performance status; additional parame

83 hat can play an important regulatory role in liver function and provide new insights into the regulat

84 splantation lessened liver injury, recovered liver function and rescued the life of Fah-/- mice after

85 stigate periodontitis induced alterations in liver function and structure using an experimental model

86 rs and transplanted to confirm postoperative liver function and survival.

87 Liver function and the doses received by the tumor are k

88 ntigen-positive viremic patients with normal liver function and the incorporation of new biomarkers t

89 th the survival of patients despite adequate liver function and the use of a supra-selective technica

90 Changes in regional liver function and volume were correlated with the funct

91 Regional (treated/nontreated) and whole liver function and volume were determined on HBS and CT.

92 ese data sets reveal dynamic changes of core liver functions and canonical signaling pathways governi

93 ffect of the treatment on the immune system, liver functions and histology, insulin resistance and li

94 reticulum stress, resulting in impairment of liver functions and, in some cases, hepatocellular carci

95 is contraindicated in patients with impaired liver function, and activated partial thromboplastin tim

96 s of variables-inflammation, renal function, liver function, and blood glucose.

97 NA, and improved markers of kidney function, liver function, and coagulopathy versus vehicle-control

98 ion, including assessment of renal function, liver function, and complete blood count, were within no

99 Single recurrences with preserved liver function, and no portal hypertension were treated

100 score, lung injury, cardiac performance and liver function, and reduced levels of non-transferrin bo

101 gy, graft quality, recipient age, underlying liver function, and region.

102 t, including sternal wound closure, improved liver function, and substantial resolution of infected s

103 pathway, its role in cell-cell adhesion and liver function, and the cell type-specific roles of Wnt/

104 velopment of a paper-based device to measure liver function, and the development of a device to ident

105 metabolites and markers of inflammation and liver function, and were monitored.

106 lation in regulation of gastrointestinal and liver functions, and how alterations in glycosylation se

107 All transplanted livers functioned, and serum transaminases, bilirubin, i

108 year, anemia, depression, abnormal renal or liver function, anticonvulsant use, labile international

109 The most important biomarkers for liver function are bilirubin and prothrombin time expres

110 Major liver functions are tightly linked to the 3D assembly of

111 androgen excess, affects maternal and fetal liver function as demonstrated by increased triglyceride

112 B medications, need consistent monitoring of liver function as part of their standard of care.

113 Complete blood counts, renal and liver function assessments, previous therapies, pain med

114 Adverse event profiles and liver function at EOP were similar, although kidney func

115 These patients had better liver function at inclusion than the patients without ep

116 Therefore, it is essential to monitor liver function at regular intervals and differential dia

117 fety outcomes included invasive candidiasis, liver function, bacterial infection, length of stay, int

118 s a clinically relevant measure of synthetic liver function, based on international normalized ratio

119 recurrence were compared with demographics, liver function, basic immune markers, treatment dose, an

120 After reperfusion, HMP-preserved livers functioned better and showed less hepatocellular

121 st-LT treatment of HCV-treatment may improve liver function but potentially decrease the likelihood o

122 in Zuckers without affecting BW and improved liver function by decreased lipogenesis, increased fatty

123 irculating glucogenic hormones both regulate liver function by increasing cytosolic calcium, although

124 The impairment of liver function by low environmentally relevant doses of

125 SOCS2 preserves liver function by restraining the first round of hepatoc

126 t in Atp7b(-/-) mice, an animal model of WD, liver function can be significantly improved without cop

127 combines serum creatinine levels and maximum liver function capacity (LiMAx(R)), namely the CreLiMAx

128 Liver function capacity was measured preoperatively by L

129 rrhosis severity: in patients with preserved liver function (Child A), combination therapy is recomme

130 erapy resulted in significant improvement in liver function, coagulation, incidence of encephalopathy

131 feasibility and clear safety, with improved liver function compared with standard static cold storag

132 ere identified in blood pressure, adiposity, liver function, drug therapy, symptoms, or quality of li

133 The effects on liver function due to the substitution of original phago

134 aboration, we identify objective measures of liver function/dysfunction that independently influence

135 al titers in all organs, increased levels of liver function enzymes and blood clotting times, decreas

136 mated glomerular filtration rate (eGFR), and liver function enzymes, annually for 5 years.

137 n resistance, leptin, adiponectin, resistin, liver function enzymes, fetuin-A, body composition, panc

138 tor dysfunction, but further worsens overall liver function, exacerbating hepatic failure in NPC dise

139 ellular microenvironment towards stabilizing liver functions for weeks.

140 plex (PIC) formation at post-natal expressed liver function genes and down-regulates a subset of embr

141 expression of both injury response and core liver function genes dependent on macrophage-derived WNT

142 sity resulted in significant improvements in liver function, glucose uptake and pancreatic beta-cell

143 Three months after laparotomy, her liver function had recovered, with resolution of her asc

144 Because epigenetic control of liver function has been previously implicated in the reg

145 Analysis of liver function, hepatic regeneration, and comprehensive

146 pump inhibitors to circulating metabolites, liver function, hepatic steatosis and the gut microbiome

147 The formation of ductular scaring affects liver function; however, scar-generating portal fibrobla

148 sidered upon development of tumor recurrence/liver function impairment.

149 Clinical measures of liver function improved substantially for all patients.

150 ces tumor burden and simultaneously improves liver function in a clinically relevant liver cirrhosis/

151 d perfluorooctanoic acid (PFOA) exposure and liver function in a Mid-Ohio Valley community.

152 n that stem cell-based therapies can improve liver function in a mouse model of hepatic failure.

153 r failure combines an acute deterioration in liver function in an individual with pre-existing chroni

154 These patients also had improvements in liver function in association with a substantial reducti

155 G) versus Roux-en-Y gastric bypass (RYGB) on liver function in bariatric patients with non-alcoholic

156 argeted RSPO2) in healthy mice, and improved liver function in diseased mice.

157 tive, and discriminatory method of assessing liver function in HCC that has been extensively tested i

158 to prevent fibrosis progression and improve liver function in humans.

159 lic complications due to asparaginase affect liver function in humans.

160 etic acid-enhanced MRI enables estimation of liver function in patients with chronic liver disease (C

161 hepatitis B virus (HBV) replication, improve liver function in patients with compensated or decompens

162 d steatohepatitis effectively and to improve liver function in patients with obesity-related NAFLD.

163 motor system pathology, and impair essential liver function in SMA.

164 with progressive deterioration of underlying liver function in terms of Child-Pugh class and MELD sco

165 USPIO did not affect pregnancy outcomes and liver function in the mother and the offspring, suggesti

166 diated nuclear receptor dysfunction disrupts liver function in WD and potentially in other disorders

167 red as a supplementary approach to improving liver function in WD.

168 useful PET probe for imaging and quantifying liver functions in vivo, with likely significant clinica

169 n tomography (PET) is rarely used to monitor liver function, in part because of a lack of specific im

170 transcription factors are critical for many liver functions, including metabolism, development, and

171 schars, lymphadenopathy, bacteremia, altered liver function, increased WBC counts, pathogen-specific

172 coffee consumption with serum biomarkers of liver function, inflammation, and metabolic health was e

173 monary hypertension, pulmonary inflammation, liver function, inflammatory infiltration, and microinfa

174 Liver function is also influenced by nonhepatocytic cell

175 Poorer liver function is positively associated with diabetes in

176 The effect of aneuploidy on liver function is unclear, and the degree of liver aneup

177 ular disease (CVD), as well as on kidney and liver function, is unknown.

178 ce have altered liver morphology and altered liver function leading to changes of glucose metabolism

179 e underlying liver cirrhosis and compromised liver function, limiting treatment options.

180 that Zdhhc13 deficiency results in abnormal liver function, lipid abnormalities, and hypermetabolism

181 atile and promising in vitro system to study liver function, liver diseases, drug targets and long-te

182 lites, epigenomic, immune, inflammatory, and liver function markers complemented the most important p

183 Liver function markers improved.

184 Mifepristone was well tolerated and improved liver-function markers.

185 Enzymatic liver function measured by LiMAx was closely associated

186 Poorer liver function might not cause adiposity; instead higher

187 licies must provide guidance on frequency of liver function monitoring for HIV-TB coinfected patients

188 licies must provide guidance on frequency of liver function monitoring for HIV-TB coinfected patients

189 ctiveness of two screening interventions for liver function monitoring: 1.

190 For patients with abnormal baseline liver function (n = 49 [47%]), liver function tests sign

191 Patients with normal baseline liver function (n = 55 [52%]) maintained similar enzyme

192 During this process, other vital liver functions need to be preserved, such as maintenanc

193 Liver function of 113 patients with liver cirrhosis was

194 Liver function of the treated part declined after radioe

195 ce and Cyld/Relb(DeltaLPC) mice had improved liver function on the DDC diet compared with control mic

196 survival and the majority not adjusting for liver function or lead-time bias.

197 Significant impairment of liver function or overt liver failure as the cause of de

198 eated human liver specimen maintained stable liver function over the entire perfusion period.

199 Liver function parameters normalized after 1 month of tr

200 nalyzed for viral kinetics and for renal and liver function parameters.

201 ocumented that miRNA ratios closely followed liver function recovery after partial hepatectomy.

202 e preoperative test to predict postoperative liver function recovery and thereby determine the optima

203 The dynamical changes during liver function recovery indicate a possible role in indi

204 In patients with normal liver function, recurrence was also significantly higher

205 hways, whereas less aggressive ones maintain liver function-related pathways that are elevated in the

206 (ECMs) alone yield iHeps with low levels of liver functions relative to adult primary human hepatocy

207 Accuracy of in-situ liver function screening was validated by 96 separate te

208 mean HAS- BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predispositi

209 mean HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predispositi

210 ore >=5 in 49%, hypertension, abnormal renal/liver function, stroke, bleeding history or predispositi

211 a mean HASBLED (hypertension, abnormal renal/liver function, stroke, bleeding predisposition/history,

212 re based on hypertension, abnormal renal and liver function, stroke, prior major bleeding, labile int

213 ne receptor (CAR or NR1I3) regulates several liver functions such as drug and energy metabolism and c

214 e disease; and had cardiac, lung, renal, and liver function sufficient to tolerate chemotherapy.

215 patients with EASL-alone ACLF have preserved liver function, suggesting the need for more liver-speci

216 Five (15%) patients had liver function test (LFT) results that were more than ei

217 two patients at that dose level) and grade 4 liver function test abnormalities (in one patient).

218 The liver function test and histological study revealed mini

219 standardized GI symptoms questionnaires and liver function test checks on admission to better quanti

220 ters are associated with mithramycin-induced liver function test elevations, and the present results

221 n (EAA) using clinical biomarkers, including liver function test enzymes (LFTs) and clinical measures

222 finitely related to the study drug: abnormal liver function test results (n=1), prolonged QT interval

223 Thyroid and liver function test results were normal, but she had rap

224 results, including complete blood count; and liver function test results were normal.

225 results, including complete blood count; and liver function test results were normal.[Figure: see tex

226 ated with patient survival, acute rejection, liver function test results, recurrence of viral or othe

227 th associated complete blood count (CBC) and liver function test results, were retrospectively review

228 g, and/or diarrhea, and 3 developed abnormal liver function test results.

229 blood count, glomerular filtration rate, and liver function test were obtained at baseline and on fol

230 ass index (BMI), HBV DNA level, HBsAg level, liver function test, complete blood count, aspartate ami

231 l individuals have complete normalization of liver function testing between episodes.

232 h reversible, elevated liver enzymes; hence, liver function testing is needed to identify those unsui

233 tes of infection, rash, and abnormalities on liver-function testing were higher with daclizumab HYP t

234 mas (34 [10%]), rash (30 [9%]), and abnormal liver function tests (38 [11%]) in the vemurafenib group

235 al blood counts, electrolytes, and renal and liver function tests (including lactic acid dehydrogenas

236 ife follow-up schedule including hepatic US, liver function tests (LFT), and a confirmatory CT/MRI.

237 Abnormal liver function tests (LFTs) are reported frequently in h

238 ture resolution, improvement in symptoms and liver function tests (LFTs), stricture recurrence and co

239 om a brain-death donor was declined for high liver function tests (LFTs).

240 , serious adverse events related to abnormal liver function tests (OR 11.19, 95% CI: 2.09-60.02) or p

241 Inclusion criteria were liver function tests 2.5 times the upper limit of normal

242 ea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect

243 temic hemodynamics were measured, along with liver function tests and clinical outcomes.

244 e events, the most common being elevation of liver function tests and pyrexia, most of which resolved

245 re cohort, these miRNAs were correlated with liver function tests and were independent predictors of

246 Our study included 602 IBD patients, with liver function tests at regular intervals.

247 No changes in liver function tests between treatment arms were observe

248 Liver function tests decreased from baseline to end of t

249 However, traditional liver function tests do not provide quantitative data ab

250 serum erythrocyte protoporphyrin levels and liver function tests following treatment were assessed.

251 sistance, serum ferritin, lipid profile, and liver function tests improved irrespective of bloodletti

252 ere presentation and persistent elevation of liver function tests in many.

253 y periodic surveillance with hepatic USG and liver function tests scheduled every 6 months for the fi

254 rmal baseline liver function (n = 49 [47%]), liver function tests significantly improved from baselin

255 egorized with NAFLD Activity Score (NAS) and liver function tests were done before surgery and after

256 At EOP, liver function tests were similar but creatinine clearan

257 Reliance on abnormal liver function tests will miss most patients with signif

258 imary care initiated strategies: (1) routine liver function tests with follow-up ultrasonography for

259 luated by physiologic monitoring, changes in liver function tests, adverse events, and radiopharmaceu

260 chimerism, recipient immune reconstitution, liver function tests, and graft survival were determined

261 acteristics, including pretreatment history, liver function tests, and PET/CT parameters, were assess

262 NA, HCV genotype (nucleic acid tests [NAT]), liver function tests, and platelet counts; patient age w

263 Unit (ICU) and hospital stay, postoperative liver function tests, fatty acid and eicosanoid concentr

264 ied secondary outcomes, including adiposity, liver function tests, incidence of conjugated hyperbilir

265 indices with the severity of liver disease, liver function tests, insulin growth factor-1 (IGF-1) an

266 Postoperative liver function tests, intensive care unit stay, hospital

267 Associations with abnormal liver function tests, somnolence, sedation and pneumonia

268 -10 x10(9)/L), and an obstructive pattern on liver function tests, with a total bilirubin level of 3.

269 stasis had abnormal findings on simultaneous liver function tests.

270 amination to her family doctor with abnormal liver function tests.

271 ic control, blood pressure, lipid tests, and liver function tests.

272 uence postoperative AST peak values or other liver function tests.

273 difference was found in other postoperative liver function tests.

274 vity of liver disease, which is reflected by liver function tests.

275 alongside elevated inflammatory markers and liver function tests.

276 thromboses, deaths, or persistent changes in liver-function tests were observed.

277 pyrexia, somnolence, and abnormal results on liver-function tests.

278 ceptible to early transient deterioration of liver function than after SG.

279 adioembolization induces regional changes in liver function that are accurately detected by HBS.

280 city (LDH), energy metabolism (glucose), and liver function (total bile acids).

281 We evaluated the impact of PVR-TIPS on liver function, transplant eligibility, and long-term ou

282 l survival outcomes are affected by baseline liver function, tumor size, and AFP level.

283 All the patients had at least one abnormal liver-function value; all persistent elevations were gra

284 ned parameters of cholesterol metabolism and liver function values in serum (n = 28) and gallstones (

285 Liver function was assessed by clearance of indocyanine

286 ood samples were collected and analyzed, and liver function was evaluated.

287 Greatest impact on liver function was found in animals with polymicrobial s

288 for 9 months) initiated post-transplant when liver function was stabilized.

289 Liver function was stable in all patients, although reve

290 In contrast, full restoration of liver functions was found in the normal group with the s

291 rogressed on sorafenib, and had Child-Pugh A liver function were enrolled.

292 , no differences in baseline demographics or liver function were observed between cohorts.

293 on in all individuals, and no differences in liver function were observed in individuals with a liver

294 rmal level, while total bilirubin (TBIL) and liver function were significantly improved.

295 Serum markers of liver function were used to evaluate LR and liver dysfun

296 adult mice displayed greater variability in liver function, which correlated with an acute-phase inf

297 d systemic inflammation, and, in men, poorer liver function, which is a marker of high alcohol consum

298 s 0 or 1, adequate respiratory, cardiac, and liver function, white blood cell count at least 3 x 10(9

299 stages of disease, including improvement in liver function with hepatic "recompensation," reduction

300 ets being both deleterious and beneficial to liver function; with increasingly novel methods of manip